key: cord-308390-ei96iuw3
authors: Wu, Junping; Tan, Cherie S.; Yu, Hongzhi; Wang, Youwei; Tian, Yutao; Shao, Wenwei; Zhang, Yifei; Zhang, Kuo; Shao, Hongxia; Ni, Guangjian; Shen, Jun; Galoforo, AntonioCarlo; Wu, Qi; Ming., Dong
title: Recovery of Four COVID-19 Patients via Ozonated Autohemotherapy
date: 2020-11-04
journal: Innovation (N Y)
DOI: 10.1016/j.xinn.2020.100060
sha: 
doc_id: 308390
cord_uid: ei96iuw3

We report a case series of ozonated autohemotherapy of four COVID-19 patients, classified as critically ill (1 patient), severe (1 patient), and moderate (2 patients). Each ozonated autohemotherapy treatment was performed at a concentration of 40 μg/ml of ozone per 100 ml of blood. The number of treatments varied from 1 to 9 depending on the disease severity. All 4 patients, including 1 critically ill patient with severe acute respiratory distress syndrome (ARDS) and life-threatening refractory hypoxemia, recovered uneventfully and were discharged from the hospital after viral clearance. The younger sibling of the critically ill patient was also diagnosed with COVID-19 and developed ARDS with hypoxemia, who received mechanical ventilation through an endotracheal tube and extracorporeal membrane oxygenation (ECMO) support. The overall medical cost for 18 days spent in the intensive care unit (ICU) and 56 days of hospitalization was $139,935 USD. On the other hand, our critically ill patient underwent 9 ozonated autohemotherapy treatments and spent 10 days in the ICU and was discharged on hospital day 30; his hospitalization cost amounted to $15,466.50 USD. This case series suggests that ozonated autohemotherapy may be an alternative noninvasive medical treatment for COVID-19 patients.

extensive lung damage in both SARS-CoV and MERS-CoV patients. 10,11 These findings 53 indicate that ozonated autohemotherapy may be a new strategy to treat patients infected 54 with betacoronaviruses. Therefore, we present, for the first time, a case series of four 55 patients with different disease severities for whom ozonated autohemotherapy 56 treatments were designed and implemented by a multidisciplinary team.

Four patients (age range, 56-77 years; 2 women) were treated with ozonated 58 autohemotherapy. Two were smokers, and 3 of the 4 had no preexisting medical 59 conditions ( Table 1 ). All 4 patients received antiviral agents, comprising lopinavir/ritonavir 60 and interferon-alpha, and three patients (patients 1, 2, and 3) were treated with steroids 61 (Table 1) .

Upon admission, two of the four patients (patients 1 and 2) had fever, although no 63 patient had a temperature above 39 °C. Other symptoms included cough (patients 2 and 

Clinical features of patients infected with

The effect of rectal ozone on the portal vein 176 oxygenation and pharmacokinetics of propranolol in liver cirrhosis (a preliminary human 177 study)

Effects of ozone on isolated peripheral blood mononuclear 179 cells

The Ozone Paradox: Ozone Is a

Strong Oxidant as Well as a Medical Drug

Molecular mechanisms in cognitive frailty: 183 potential therapeutic targets for oxygen-ozone treatment

Medical ozone promotes Nrf2 185 phosphorylation reducing oxidative stress and pro-inflammatory cytokines in multiple 186 sclerosis patients

Hydrogen peroxide as second messenger in lymphocyte activation

Plasma inflammatory cytokines and 190 chemokines in severe acute respiratory syndrome

MERS-CoV infection in humans is 192 associated with a pro-inflammatory Th1 and Th17 cytokine profile

Chinese Center for Disease Control and Prevention. Chinese Clinical Guidance for 194 COVID-19 Pneumonia Diagnosis and Treatment

Creatine kinase (U/L; normal range